Efficacy and safety of faropenem in pediatric patients with bacterial infectious diseases

DOI Web Site 2 Citations 14 References

Bibliographic Information

Other Title
  • 小児細菌感染症に対するfaropenemの有効性および安全性の検討
  • ショウニ サイキン カンセンショウ ニ タイスル faropenem ノ ユウコウセイ オヨビ アンゼンセイ ノ ケントウ

Search this article

Abstract

The only oral penem antibiotic, faropenem (FRPM: Farom ®r y Syrup for pediatrics), is one of the few antibiotics that exerts potent antibacterial activity against penicillin-resistant Streptococcus pneumoniae (PRSP), and the dosage and administration schedule has been established for children.<BR>We studied the efficacy and safety of the drug in 113 pediatric patients with mild-to-moderate bacterial infectious diseases: upper respiratory tract infection (pharyngitis or tonsillitis), acute bronchitis, otitis media and urinary tract infection (UTI). The patients were administered oral FRPM at the dose of 15-30mg/kg/day three times a day for 3 to 8 days (or 5 to 14 days for group A streptococcal infection).<BR>The study drug was found to be clinically effective in 63/70 cases (90.0%) of upper respiratory tract infection, 6/7 cases of acute bronchitis, 16/17 cases (94.1%) of otitis media and 6/6 cases of UTI. FRPM was demonstrated to have very potent antibacterial activity against S. pneumoniae, with a high bacteriological eradication rate. No serious adverse drug reactions were observed. The only side effect was diarrhea in 12.5% of the patients (14/112 cases). There was little difference in the incidence of diarrhea between FRPM and other oral beta-lactam antibiotics. Compliance with FRPM was found to be very good in this study.<BR>These findings suggest that FRPM is as useful for the treatment of bacterial infectious diseases in children as oral penicillin and cephem antibiotics.

Journal

Citations (2)*help

See more

References(14)*help

See more

Details 詳細情報について

Report a problem

Back to top